Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to invest in the U.S. as tariffs targeting the industry loom. The facility ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

Merck on Thursday lowered its full-year profit guidance, citing $200 million in estimated costs for tariffs and a charge tied to a recent deal. The company now expects its 2025 adjusted earnings ...